Nemolizumab (Nemluvio, Galderma) Shows “Sustained and Increased” Improvements in Itch and Skin Lesions in AD Patients for Up to Two Years June 6, 2025
AD Pipeline Update: LEO Pharma Reports Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe AD May 12, 2025
